Carlyle Group acquired Knack RCM and EqualizeRCM last month, merged them, and is already inviting investment bank pitches for a potential India IPO. When PE looks at an offshore RCM delivery platform and says "this is public-market worthy," the whole industry needs to pay attention.
Employees across Knack RCM's 10 delivery centers in India, the Philippines, and the US — supporting US healthcare clients across clinical, financial, and technology RCM functions.
Last month, Carlyle Group acquired majority stakes in both Knack RCM and EqualizeRCM, merging them into a combined entity. This week, per Bloomberg and Business Standard reporting, Carlyle is inviting investment banks to pitch for advisory mandates on a potential India IPO of the combined platform. Banker presentations are happening now; advisers are expected to be appointed soon. IPO size and valuation are not yet determined.
Knack RCM is a Woodbridge, NJ-based operation with more than 8,000 employees spread across 10 delivery centers in India, the Philippines, and the United States. The platform supports US healthcare clients across clinical services, financial operations, and technology-enabled RCM. EqualizeRCM brings complementary capabilities — together they form a scaled, multi-specialty, multi-geography RCM delivery platform.
The choice to pursue an India IPO — rather than a US listing or PE-to-PE sale — is deliberate and worth unpacking.
The most important thing about this move is not the mechanics of the IPO. It's what the decision to pursue public markets tells you about how Carlyle values the offshore RCM model.
PE firms don't pursue IPOs on assets they aren't confident in. The IPO process is expensive, time-consuming, and requires a credible growth narrative that will hold up to institutional scrutiny. Carlyle wouldn't be inviting bankers if they weren't confident the combined Knack + EqualizeRCM entity could command a compelling public market valuation and tell a compelling story to equity investors.
That's a direct statement about where PE believes the offshore RCM market is: scaled enough, durable enough, and growing fast enough to go public. For anyone who still thinks of offshore RCM as a cost-cutting tactic on the margins of a health system's operations, this is a correction. The market has moved past that framing.
Across India, Philippines, and US — Knack RCM isn't a BPO vendor running a small offshore team. It's a vertically integrated labor platform spanning clinical documentation, coding, AR, and technology services for US healthcare clients.
The choice of India as the listing venue is a deliberate capital markets strategy, not a default. India's public markets for healthcare services companies have remained robust even as the broader Nifty 50 index has declined more than 10% this year. Indian institutional investors have demonstrated consistent appetite for healthcare-adjacent businesses, particularly those with exposure to the US market — which is perceived as structurally growing and defensible.
A US listing would have put Carlyle in front of investors who understand domestic healthcare economics but may apply a BPO discount to an offshore-heavy delivery model. An India listing puts them in front of investors who understand the offshore services business model deeply, appreciate the labor cost structure, and have a framework for valuing healthcare services delivery companies.
The India route may also allow Carlyle to retain more upside on the US private equity side. If the India-listed entity holds the offshore delivery operations and the US-based relationships remain in a separate structure, there's flexibility in how value is ultimately captured and distributed across the deal.
The practical implications for RCM leaders are real, even if the IPO timeline is months away.
First, the consolidation at this scale means the offshore RCM vendor landscape is changing. You are increasingly dealing with fewer, larger counterparties. Knack + EqualizeRCM as a standalone PE-backed entity had limited leverage in contract negotiations. As a PE-backed combined platform pursuing public markets, they have a very different set of incentives — growth, margin expansion, client retention metrics that hold up to analyst scrutiny. That changes the relationship dynamic.
Any offshore RCM vendor backed by PE has an exit horizon. Whether it's an IPO, a strategic sale, or a secondary buyout, the ownership change will affect your contract terms, your service continuity, and the attention you get from leadership. Know who owns your vendor and what they're planning.
Second, a publicly listed offshore RCM platform will face quarterly pressure to demonstrate margin improvement. For US health system clients, that pressure can translate to scope reduction, price increases at renewal, or staff attrition at the delivery center level when cost targets get aggressive. Understand this going in.
Third — and this is underappreciated — the scale that Knack + EqualizeRCM represents signals where the offshore model is going. 8,000 employees across clinical, financial, and technology functions is not a vendor running your coding team. It's a platform that can handle almost the entire RCM function end-to-end. The competitive pressure this creates for domestic RCM operations is real and growing.
Combine this with the Med-Metrix/CanAide deal announced the same week, and you start to see the shape of where RCM is consolidating: PE-backed platforms are building full-stack operations at scale, whether through acquisitions of front-end patient access capabilities or through public market capitalization of offshore delivery infrastructure. The fragmented, best-of-breed vendor landscape that defined RCM procurement a decade ago is being replaced by fewer, larger operators with deeper capitalization and broader scope.
For health systems, the calculus is shifting. The vendor options are consolidating. The platforms getting bigger are getting harder to replace. The leverage in negotiations is moving.
The question every RCM leader should be asking right now is simple: does your offshore vendor have a PE exit strategy? Because if they do, their incentives are no longer primarily aligned with your operational outcomes — they're aligned with a valuation event. And that changes everything about how you should manage that relationship.
M&A moves, offshore market shifts, and PE activity — delivered every morning. Free.
Subscribe Free →Reaching RCM decision-makers? Advertise with RevCycleAI →